ropinirole has been researched along with Atherosclerotic Parkinsonism in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Rotenone is a neurotoxin that selectively destroys dopaminergic neurons, leading to PD-like symptoms." | 1.56 | Neuroprotective Effect of Quercetin in Combination with Piperine Against Rotenone- and Iron Supplement-Induced Parkinson's Disease in Experimental Rats. ( Raj, K; Sharma, S; Singh, S, 2020) |
| "They display some memory deficits as in human Parkinson's desease." | 1.31 | The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome. ( Baillet, C; Callizot, N; Guénet, JL; Poindron, P; Warter, JM, 2001) |
| "Ropinirole did not cause marked stereotypies." | 1.28 | Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist. ( Costall, B; Domeney, AM; Eden, RJ; Gerrard, PA; Harvey, CA; Kelly, ME; Naylor, RJ; Owen, DA; Wright, A, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Sharma, S | 1 |
| Raj, K | 1 |
| Singh, S | 1 |
| Wang, Y | 1 |
| Bouabid, S | 1 |
| Darvas, M | 1 |
| Zhou, FM | 1 |
| Carta, AR | 1 |
| Frau, L | 1 |
| Pinna, A | 1 |
| Morelli, M | 1 |
| Thomas, A | 1 |
| Bonanni, L | 1 |
| Di Iorio, A | 1 |
| Varanese, S | 1 |
| Anzellotti, F | 1 |
| D'Andreagiovanni, A | 1 |
| Stocchi, F | 1 |
| Onofrj, M | 1 |
| Pearce, RK | 1 |
| Banerji, T | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Callizot, N | 1 |
| Guénet, JL | 1 |
| Baillet, C | 1 |
| Warter, JM | 1 |
| Poindron, P | 1 |
| Eden, RJ | 1 |
| Costall, B | 1 |
| Domeney, AM | 1 |
| Gerrard, PA | 1 |
| Harvey, CA | 1 |
| Kelly, ME | 1 |
| Naylor, RJ | 1 |
| Owen, DA | 1 |
| Wright, A | 1 |
1 trial available for ropinirole and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinson's disease.
Topics: Benzothiazoles; Dopamine Agonists; Double-Blind Method; Endpoint Determination; Female; Humans; Indo | 2006 |
6 other studies available for ropinirole and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Neuroprotective Effect of Quercetin in Combination with Piperine Against Rotenone- and Iron Supplement-Induced Parkinson's Disease in Experimental Rats.
Topics: Alkaloids; Benzodioxoles; Corpus Striatum; Dietary Supplements; Drug Synergism; Electron Transport C | 2020 |
The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons.
Topics: Animals; Antiparkinson Agents; Dopaminergic Neurons; Homeodomain Proteins; Indoles; Male; Mice; Mice | 2020 |
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Corpus Striatum; Dopamine Agoni | 2010 |
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Bromocriptine; Callithr | 1998 |
The frissonnant mutant mouse, a model of dopamino-sensitive, inherited motor syndrome.
Topics: Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Corpus Striatum; Disease Models, Anima | 2001 |
Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenylyl Cyclases; Animals; Antiparkinson Agents; Bloo | 1991 |